These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 2716940)

  • 1. [Pharmacokinetics of cyclosporin A in patients with nephrotic syndrome].
    Moulin B; Vernillet L; Dadoun C; Le Bigot JF; Godin M; Fillastre JP
    Nephrologie; 1989; 10(1):17-22. PubMed ID: 2716940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome.
    Vernillet L; Moulin B; Dadoun C; Le Bigot JF; Fillastre JP
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):529-35. PubMed ID: 3363653
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of drugs in patients with the nephrotic syndrome.
    Gugler R; Shoeman DW; Huffman DH; Cohlmia JB; Azarnoff DL
    J Clin Invest; 1975 Jun; 55(6):1182-9. PubMed ID: 1133166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure.
    Levels JH; Lemaire LC; van den Ende AE; van Deventer SJ; van Lanschot JJ
    Crit Care Med; 2003 Jun; 31(6):1647-53. PubMed ID: 12794399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [About two cases of massive hypercholesterolemia].
    Perier C; Raby N; Atieh S; Granouillet R; Chamson A
    Ann Biol Clin (Paris); 2005; 63(2):217-9. PubMed ID: 15771981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
    Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute changes in concentrations of apolipoproteins A-I, B, C-II and lipoprotein(a) in serum covering the period from directly before to 48 hours after chronic haemodialysis.
    Schumacher M; Kessler A; Bahlmann G; Wood WG
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):123-5. PubMed ID: 8031962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol metabolism in glomerular cells: effect of lipoproteins from nephrotic patients.
    Wanner C; Krämer-Guth A; Nauck M; Quaschning T; Pavenstädt H; Schollmeyer P
    Miner Electrolyte Metab; 1996; 22(1-3):39-46. PubMed ID: 8676822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased high density lipoprotein cholesterol in adult nephrotic syndrome in Nigeria.
    Adigun MO; Agbedana EO; Kadiri S; Taylor GO
    Afr J Med Med Sci; 1999; 28(1-2):97-100. PubMed ID: 12953996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
    Weber M; McNicoll S; Marcil M; Connelly P; Lussier-Cacan S; Davignon J; Latour Y; Genest J
    Can J Cardiol; 1997 Mar; 13(3):253-60. PubMed ID: 9117913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma lipids and lipoprotein-cholesterol distribution in nephrotic syndrome patients during short term high dose steroid treatment.
    Arije A; Erasmus RT; Anjorin SA
    Cent Afr J Med; 1993 Oct; 39(10):211-5. PubMed ID: 8020077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group.
    Connelly PW; Poapst M; Davignon J; Lussier-Cacan S; Reeder B; Lessard R; Hegele RA; Csima A
    Can J Cardiol; 1999 Apr; 15(4):409-18. PubMed ID: 10322250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of apoprotein epsilon 2 homozygosity on nephrotic hyperlipidemia.
    Joven J; Vilella E
    Clin Nephrol; 1997 Sep; 48(3):141-5. PubMed ID: 9342484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum apolipoprotein abnormalities in patients with idiopathic nephrotic syndrome].
    Zhang H; Huang WC; Tang SC
    Zhonghua Yi Xue Za Zhi; 1994 Sep; 74(9):542-4, 582-3. PubMed ID: 7842352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
    Variol P; Nguyen L; Tranchand B; Puozzo C
    Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose response kinetics of cyclosporine.
    Bozkurt F; Stierle H; Schollmeyer P; Keller E
    Clin Nephrol; 1987 Jul; 28(1):10-4. PubMed ID: 3304744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of plasma oncotic pressure on apolipoprotein levels in rats with Heymann nephritis.
    Kaysen GA; Jones H; Joles JA; van Tol A
    Miner Electrolyte Metab; 1996; 22(1-3):31-8. PubMed ID: 8676821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of renal transplantation on plasma lipids and lipoprotein lipase in children with congenital nephrosis.
    Antikainen M; Holmberg C; Taskinen MR
    Clin Nephrol; 1994 May; 41(5):284-9. PubMed ID: 8050208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of oral cyclosporin A in diabetic children and adolescents.
    Misteli C; Rey E; Pons G; Richard MO; d'Athis P; Legrand A; Bougneres P; Olive G
    Eur J Clin Pharmacol; 1990; 38(2):181-4. PubMed ID: 2338116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.